Ads
related to: lipitor pfizer dosis 3
Search results
Results From The WOW.Com Content Network
In 1996, Warner-Lambert entered into a co-marketing agreement with Pfizer to sell Lipitor, and in 2000, Pfizer acquired Warner-Lambert for $90.2 billion. [115] [105] [111] [112] Lipitor was on the market by 1996. [113] [116] By 2003, Lipitor had become the best selling pharmaceutical in the United States. [109]
Cerivastatin (INN, [1] brand names: Baycol, Lipobay) is a synthetic member of the class of statins used to lower cholesterol and prevent cardiovascular disease.It was marketed by the pharmaceutical company Bayer A.G. in the late 1990s, competing with Pfizer's highly successful atorvastatin (Lipitor).
The best-selling statin is atorvastatin, also known as Lipitor, which in 2003 became the best-selling pharmaceutical in history. [12] The manufacturer Pfizer reported sales of US$12.4 billion in 2008. [13] Patient compliance with statin usage is problematic despite robust evidence of the benefits. [14] [15]
Pfizer has been no stranger to the kind of damage that blockbuster drug patent expirations can inflict. The company's high-flying cholesterol fighter, Lipitor, has struggled since losing its ...
Pfizer (NYS: PFE) no longer has exclusivity on the drug as of today. We've known about this day for years after Pfizer settled 3 Things More Important to Pfizer Than Losing Lipitor
Pfizer (NYS: PFE) used to sell Lipitor exclusively in the United States. And it was a huge component of the company's revenue and earnings. Honest. I swear. You certainly wouldn't know it from the ...
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug. In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [ 1 ]
Lately, almost every day we've heard of a new Pfizer (NYS: PFE) strategy for hanging on to Lipitor sales after the drug faces generic competition. Discounts, co-pay cards, rebates, conversion to ...